This Phase II study investigated the efficacy of BIBF 1120 in 73 patients with an ECOG score of 0-2 with locally advanced or metastatic non-small cell lung cancer (NSCLC) (stage 11B/IV).
Of particular note were results from a subset of 57 patients with ‘good disease state’ (ECOG performance status of zero or one): these patients experienced longer overall survival (median overall survival was 9.5 months), longer progression-free survival (PFS; median PFS was 2.9 months) and a higher stable disease rate of 59% compared with the overall study population.
Andreas Barner, vice chairman of the board of managing directors at Boehringer Ingelheim, said: “These new BIBF 1120 Phase II data, coupled with evidence from previous studies that show BIBF 1120 is well tolerated in combination with standard lung cancer treatments, gives us great confidence in moving forward with further investigations of BIBF 1120 in lung cancer.”